Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
October 18, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous...
Provectus Biopharmaceuticals Announces Presentation of PV-10® Pancreatic Cancer Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 16, 2020 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) presented non-clinical data from ongoing research on...
Biodesix Presents Positive Data in Detection of Primary Immunotherapy Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
October 22, 2018 03:00 ET
|
Biodesix, Inc.
Serum Proteomic Test Could Optimize Treatment by Identifying Patients Unlikely to Benefit from Immunotherapy BOULDER, Colo. and MUNICH, Germany, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Biodesix®...
Biodesix Announces Biomarker Research Collaboration with Checkmate Pharmaceuticals
March 20, 2018 09:00 ET
|
Biodesix, Inc.
BOULDER, Colo., March 20, 2018 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Boulder, CO, USA), a molecular diagnostics company has entered into a biomarker research collaboration with Checkmate...
Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In Patients
November 07, 2017 12:22 ET
|
Biodesix, Inc.
BOULDER, Colo., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Biodesix® chief technology officer, Dr. Heinrich Roder, will give an oral presentation discussing a proprietary test development methodology that...
Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry
November 01, 2017 12:12 ET
|
Biodesix, Inc.
BOULDER, Colo., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Biodesix® presented preliminary data evaluating a blood-based PD-L1 assay to identify patients who may benefit from cancer immunotherapies. The data...
Biodesix To Present Data at SITC Annual Meeting
October 25, 2017 10:00 ET
|
Biodesix, Inc.
BOULDER, Colo., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Biodesix will conduct an oral presentation on immunotherapy biomarkers in addition to presenting data from two separate studies at the SITC 2017...